Market News How it works Learn FAQ
| RCT 0.132 73.46% | NU 12.36 -18.47% | EWZ 33.885 -20.44% | TGL 0.254 14.67% | SRTM 0.326 -24.24% | BBD 2.855 -29.85% | ITUB 7.6 -21.41% | AZTR 1.615 125.87% | SHFS 0.103 -22.21% | XP 15.575 -48.78% | GCDT 0.1361 -22.71% | CLRO 4.79 47.38% | SOXL 91.64 9.67% | SPCX 149.92 1.65% | NWGL 0.0829 1.10% | PBR 21.94 -16.13% | NVD 3.99 -4.77% | SGRY 23.0703 46.48% | TSLL 10.9599 12.29% | VALE 11.99 -3.31% | RBNE 0.1701 -10.47% | CRWV 57.4626 5.95% | INTC 90.785 4.40% | NVDA 216.2072 2.49% | SOXS 47.41 -9.63% | BITO 10.77 -0.55% | ABEV 2.8 -15.15% | IREN 26.5486 6.60% | JBLU 2.295 -12.57% | NOK 8.625 5.96% | XTND 2.2 24.29% | SPRC 1.5001 37.62% | GPUS 0.1782 5.51% | TQQQ 69.14 4.30% | SBS 4.765 -25.55% | INTR 4.6286 -35.62% | TSLG 5.48 12.53% | RWM 14.435 -0.79% | TSLA 395.443 6.24% | SPDN 8.475 -0.76% | SQQQ 37.975 -4.30% | AAL 12.2055 0.79% | SID 0.9269 -21.45% | GGB 4.765 -6.57% | PBR-A 19.3388 -17.81% | RENT 2.9015 26.15% | LUCD 0.5155 25.43% | CIFR 8.1475 2.61% | KORU 10.9537 3.53% | WULF 12.08 6.71%
ATAlterity Therapeutics Limited logo

Alterity Therapeutics Limited (ATHE)

NASDAQ Capital Market · Currency in USD
$2.01 ▼ -0.08 (-3.83%)
As of Oct 26, 12:31 PM ET. Market open.

Summary

Previous Close
$2.09
Open
$2.01
Day's Range
$2.01 – $2.01
52 Week Range
$2.01 – $5.89
Volume
6,646
Avg. Volume
20,809
Market Cap
$34.05M
Beta (5Y Monthly)
-0.03
PE Ratio (TTM)
--
EPS (TTM)
-$64.55
Earnings Date
Mar 4, 2027
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$8.00

Profile: Alterity Therapeutics Limited

Sector
Healthcare
Industry
Biotechnology
Full-time employees
11
CEO
David A. Stamler

Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease.

Earnings

Next report: Thu, Mar 4, 2027
EPS estimate -$0.03
DateEst.Actual
Aug 28, 2026-$0.12-$0.05Beat
Feb 25, 2026-$0.25-$0.42Miss
Aug 28, 2025-$0.56-$0.34Beat
Feb 28, 2025-$0.69-$0.57Beat
Feb 3, 2025–-$0.00
Aug 29, 2024-$0.07-$0.80Miss

Analyst view

Consensus price target
$8.00 ▲ +298.0%
Range $2.00 – $12.00
Rating: Buy
Buy 50% · Hold 50% · Sell 0%

Get free alerts on ATHE and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.